Preclinical and Translational Pharmacology of Afucosylated Anti-CCR8 Antibody for Depletion of Tumour-Infiltrating Regulatory T Cells

Researchers reported findings from preclinical studies characterizing pharmacology, pharmacokinetics/pharmacodynamics, and safety profile of RO7502175, an afucosylated antibody designed to eliminate C–C motif chemokine receptor 8 (CCR8)⁺ Treg cells in the tumor microenvironment through enhanced antibody-dependent cellular cytotoxicity.